VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
InnoCare's BTK Inhibitor Orelabrutinib NDA Accepted for Autoimmune Disease Indication — ITP
InnoCare's BTK Inhibitor Orelabrutinib NDA Accepted for Autoimmune Disease Indication — ITP
May 29, 2026 11:03 CST Updated 16:40
Share:
InnoCare
Innovative Drug Developer
